Targeted drugs are constantly available, and breast cancer may become a manageable chronic disease

Cancer is considered an incurable medical problem, and so far, medical professionals are still trying to develop more new ways to treat it.
2018, the world's first cell cycle protein-dependent kinase (CDK4/6 inhibitor Aiboxin ® IBRANCE® (Pybersili, palbociclib) won China's national drug regulatory The Authority approved the treatment of localized advanced or metastatic breast cancer that is positive for hormone-like (HR) and negative for human skin growth factor 2 (HER2) and should be used in union with aromatase inhibitors as an initial endocrine treatment for post-menopenerial female patients.
With the clinical application of CDK4/6 inhibitors in advanced breast cancer, the total survival of breast cancer patients has been greatly improved, said Professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital affiliated with Shanghai Jiaozhou University School of Medicine.
early treatment of breast cancer, late-stage hard-to-cure breast cancer has become a threat to women's health of the primary malignant tumor, the global average of 18 women in a lifetime will develop breast cancer.
, the situation of advanced breast cancer in China is still serious.
According to a report released by the National Cancer Center, the incidence of breast cancer in China ranks first among female malignancies, with an annual incidence of about 304,000, and female malignant tumor deaths account for 17.1% of all causes of death among female residents.
between 2000 and 2013, China's breast cancer growth rate averaged about 3.5% a year.
And 1 in 10 new breast cancer patients are diagnosed with advanced stage each year, and 30 to 40 percent of early stage breast cancer patients who have underwent surgery and standard treatment develop advanced breast cancer.
5-year survival rate is only 20%, the overall medium survival time is 2 to 3 years.
Professor Lin Qing, Director of the Department of Radiotherapy at the 10th People's Hospital of Shanghai, said, "At present, there are significant differences in the burden and development trend of breast cancer in women in developed and developing countries, and in Europe and the United States, the incidence of breast cancer is very high, but the mortality rate is very low."
, the five-year survival rate of breast cancer in the United States is as high as 90%, and the five-year survival rate of breast cancer in China is 83.2%.
caused by this difference may be because China's breast cancer incidence age is 10 years earlier than foreign countries, China's breast cancer incidence peak of 45-55 years old, foreign breast cancer incidence peak of 55-65 years old.
the pathogenesis of breast cancer is not yet clear, but numerous studies have confirmed that it may be related to endocrine disorders, breast development, genetic factors, and eating habits.
, early stage breast cancer often does not have typical symptoms, most of which are detected through physical examination and breast cancer screening.
is "early cure, late cure" for any cancer.
Although advanced breast cancer is currently difficult to cure, it can help patients with advanced stages to alleviate clinical symptoms, improve quality of life, and further prolong their survival by optimizing treatment patterns, improving access to innovative drugs and equity in health care.
, director of the radiotherapy department at the 10th People's Hospital of Shanghai.
advanced breast cancer can not be cured, but can be treated in recent years, from surgical treatment, chemotherapy, radiotherapy, endocrine therapy to today's targeted treatment, advanced breast cancer treatment methods continue to emerge and change, especially treatment strategies from "single" to "joint" optimization, bringing about changes in the domestic pattern of late-stage breast cancer treatment and management model changes, so that patients benefit from joint treatment, survival can be greatly extended, so that breast cancer can be treated like hypertension, diabetes can be controlled.
"The choice of treatment options for patients with advanced breast cancer is very important, and how to help patients make the right treatment choices is a challenge for every oncologist," said Professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital, affiliated with Shanghai Jiaoxuan University School of Medicine.
In patients with advanced breast cancer, hormone-positive (HR-plus) breast cancer patients accounted for about 65%, of which hormone-positive (HR-plus)/human skin growth factor 2 negative (HER2-) of advanced patients accounted for about 5-10% of breast cancer patients, and different types of patients treatment methods are also different.
treatment of breast cancer in the past is relatively limited, especially for the advanced patients of HR-/HER2-, generally mainly chemotherapy and endocrine monotherapy.
, however, with the development of precision medicine, patients with advanced breast cancer have made major breakthroughs in treatment strategies and management, and the development and marketing of targeted drugs has benefited patients with advanced breast cancer more.
Professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital affiliated with Shanghai Jiaoxuan University School of Medicine, further stressed that "although it is difficult to cure advanced breast cancer patients, reasonable treatment can alleviate symptoms, improve quality of life, and significantly prolong survival, most patients have been able to achieve long-term tumor survival."
clinically, breast cancer has been gradually treated as a "chronic disease".
In recent years, with the continuous breakthrough of targeted treatment of advanced breast cancer, many new drugs have emerged, including a variety of CDK4/6 inhibitors that can reverse or delay endocrine resistance, which have good efficacy and safety, further promoting the clinical benefits of endocrine therapy and promoting the clinical benefits of endocrine resistance.
", the world's first CDK4/6 inhibitor was approved, for life "life"CDK4/6 is a key regulatory factor in the cell division cycle, can drive cell division.
CDK4/6 is an iconic feature of cancer because it is overactive in many cancers, causing the cell division cycle to spiral out of control.
, CDK4/6 inhibitors were once hailed as anti-cancer "gods".
with the listing of CDK4/6 inhibitors, the era of "CDK4/6 inhibitors and endocrine therapy" for advanced breast cancer treatment was officially launched.
also means that the treatment of HR-/HER2-advanced breast cancer ends nearly a decade without a breakthrough and innovative therapy.
CDK4/6 inhibitor is the world's first CDK4/6 selective inhibitor, pyrithroid.
clinical study data showed that the medium progression-free survival of patients treated with HR-/HER2-patients was as long as 24.8 months, while the medium non-progression survival of patients treated with monopicillin was only 14.5 months.
, the treatment of pyridoxili combined with quercin significantly extended the 10-month non-progression survival of patients with advanced breast cancer.
"In breast cancer cells, CDK4/6 inhibitors block the phosphorylation of the RB protein by inhibiting the binding of cytocytocytosin D1 and CDK4/6 kinases, thereby blocking cell cycles," said Professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital, affiliated with Shanghai Jiaozhou University School of Medicine. The progress of phase G1 to stage S inhibits tumor cell proliferation, clinically confirmed that CDK4/6 inhibitor combined endocrine therapy has a better tumor shrinkage effect than endocrine monodrive, tumor objective remission, and higher disease control rate, for HR/HER2-advanced breast cancer patients to bring survival benefits.
a number of domestic and international guidelines to recommend this joint treatment as a standard first- or second-line treatment for patients with HR/HER2-advanced breast cancer.
" it is reported that so far, Aibo new has been approved in 86 countries and regions around the world, China is the 87th.
to improve treatment is available, look forward to the inclusion of health insurance in order to allow more patients to use anti-cancer drugs, a series of policy dividends are also gradually landing, the relevant departments of the state on the "sky-high price of anti-cancer drugs" has been corresponding measures.
present, the vast majority of clinically commonly used and accurate efficacy of drugs have been included in the scope of medical insurance payments, greatly reducing the burden on patients, so that people can use life-saving drugs.
since cdK4/6 inhibitors were introduced, drug prices have become the most important concern.
currently costs about 360,000 patients a year, which is still a sky-high drug for patients in an ordinary family.
In this regard, Professor Lin Qing, Director of the Department of Radiotherapy at the 10th People's Hospital of Shanghai, said, "Targeted treatment has made a major breakthrough in the collection of advanced breast cancer, post-menoanth ER-/HER2-advanced breast cancer, the middle non-progressing survival period from 14.5 months to 24.8 months, can be said to have doubled, this breakthrough is epoch-making."
wants to make clear that new targeted drugs will be available as soon as possible, making them more accessive and enough to give hope to more families.
patients with advanced breast cancer, the proportion of first-line targeted treatment in Europe is higher than in China.
, on the one hand, patients and doctors in China have low awareness of targeted treatment, on the other hand, the financial burden is also hindering the use of drugs.
the future, if targeted treatment drugs are included in health insurance, not only will the financial burden on patients be greatly reduced, but doctors will also be able to develop appropriate treatment options for patients without too much consideration of economic factors.
" at the same time, professor Guo Shanxuan, deputy director of general surgery at the Ninth People's Hospital, affiliated with Shanghai Jiaoxuan University School of Medicine, stressed.
is understood that Pfizer has recently launched a new model of CDK4/6 inhibitors payment in China, the first time commercial insurance into breast cancer treatment payments, the development of innovative solutions to meet the health needs of patients.
With the increasing number and variety of innovative anti-cancer drugs in the health insurance catalogue, improve the access of high-quality and innovative drugs, thereby increasing the five-year survival rate of breast cancer patients, and help health China Action (2019-2030) to achieve the goal of an overall cancer survival rate of not less than 43.3% by 2022.